CN106999575A - 使用能够穿透细胞质的完整免疫球蛋白类型的抗体抑制在细胞中活化的ras的方法及其用途 - Google Patents

使用能够穿透细胞质的完整免疫球蛋白类型的抗体抑制在细胞中活化的ras的方法及其用途 Download PDF

Info

Publication number
CN106999575A
CN106999575A CN201580045140.3A CN201580045140A CN106999575A CN 106999575 A CN106999575 A CN 106999575A CN 201580045140 A CN201580045140 A CN 201580045140A CN 106999575 A CN106999575 A CN 106999575A
Authority
CN
China
Prior art keywords
chain variable
antibody
variable region
amino acid
ras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580045140.3A
Other languages
English (en)
Chinese (zh)
Inventor
金容星
崔东起
辛承敏
金圣勋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ollon Pharmaceutical
Original Assignee
Ollon Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ollon Pharmaceutical filed Critical Ollon Pharmaceutical
Priority claimed from PCT/KR2015/007627 external-priority patent/WO2016013871A1/ko
Publication of CN106999575A publication Critical patent/CN106999575A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580045140.3A 2014-07-22 2015-07-22 使用能够穿透细胞质的完整免疫球蛋白类型的抗体抑制在细胞中活化的ras的方法及其用途 Pending CN106999575A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2014-0092687 2014-07-22
KR20140092687 2014-07-22
KR10-2015-0103214 2015-07-21
KR1020150103214A KR101602876B1 (ko) 2014-07-22 2015-07-21 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
PCT/KR2015/007627 WO2016013871A1 (ko) 2014-07-22 2015-07-22 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용

Publications (1)

Publication Number Publication Date
CN106999575A true CN106999575A (zh) 2017-08-01

Family

ID=55354089

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580045140.3A Pending CN106999575A (zh) 2014-07-22 2015-07-22 使用能够穿透细胞质的完整免疫球蛋白类型的抗体抑制在细胞中活化的ras的方法及其用途

Country Status (11)

Country Link
US (1) US10851177B2 (enExample)
EP (1) EP3173099B1 (enExample)
JP (1) JP6798988B2 (enExample)
KR (2) KR101602876B1 (enExample)
CN (1) CN106999575A (enExample)
AU (1) AU2015292956B2 (enExample)
BR (1) BR112017001306A2 (enExample)
CA (1) CA2955265A1 (enExample)
IL (1) IL250137B (enExample)
MX (1) MX2017001012A (enExample)
RU (1) RU2017103679A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111936521A (zh) * 2017-11-16 2020-11-13 奥隆制药 通过内化到细胞胞浆中抑制细胞中活化的Ras的抗体及其用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
WO2017204606A1 (ko) * 2016-05-27 2017-11-30 오름테라퓨틱 주식회사 세포질 침투 항체 및 이의 용도
KR20190143826A (ko) 2018-06-21 2019-12-31 오름테라퓨틱 주식회사 세포/조직 특이적 세포 침투 항체
JP2021532135A (ja) * 2018-07-23 2021-11-25 中外製薬株式会社 標的細胞特異的な細胞質侵入抗原結合分子
WO2020149613A1 (ko) * 2019-01-15 2020-07-23 오름테라퓨틱 주식회사 세포질 침투성이 증진된 항체
MX2021013091A (es) * 2019-05-01 2021-11-17 Univ Santiago Compostela Suministro intracelular de anticuerpos anti-kras formulados en nanocapsulas.
TW202204420A (zh) * 2020-04-30 2022-02-01 美商建南德克公司 Ｋｒａｓ特異性抗體及其用途
IL307396A (en) * 2021-04-02 2023-12-01 Massachusetts Gen Hospital Methods for inhibiting RAS
WO2023003339A1 (ko) 2021-07-20 2023-01-26 아주대학교산학협력단 세포 내부에 침투하여 표적단백질을 분해하여 제거하는 세포침투 분해항체 및 이의 용도
WO2023044432A2 (en) * 2021-09-17 2023-03-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Targeting mutant kras with a mutation specific iga

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101402675A (zh) * 2008-11-28 2009-04-08 中国人民解放军第三军医大学第三附属医院 一种靶向抑制ανβ3阳性细胞增殖的环肽
WO2009134027A2 (en) * 2008-04-30 2009-11-05 Ajou University Industry-Academic Cooperation Foundation Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
KR20100045683A (ko) * 2008-10-24 2010-05-04 아주대학교산학협력단 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도
US20110263829A1 (en) * 2008-11-11 2011-10-27 Ajou University Industry Academic Cooperation Foundation Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same
CN103874710A (zh) * 2011-04-01 2014-06-18 耶鲁大学 细胞渗透型抗dna抗体和其抑制dna修复的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
CN1241574A (zh) 1998-07-02 2000-01-19 中国人民解放军第四军医大学 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体
AU2003219277A1 (en) 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
CA2506128A1 (en) 2002-11-15 2004-06-03 Medical Research Council Anti-activated ras antibodies
CA2647102A1 (en) * 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
SG189769A1 (en) 2008-01-03 2013-05-31 Scripps Research Inst Antibody targeting through a modular recognition domain
KR100849941B1 (ko) * 2008-04-29 2008-08-01 원우이에프엔지니어링주식회사 열 및 연기 화재감지장치 복합시험기
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
GB201103631D0 (en) * 2011-03-03 2011-04-13 Univ Leeds Identification of candidate therapeutics
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US9815866B2 (en) 2012-09-14 2017-11-14 Japanese Foundation For Cancer Research Peptides that bind to epithelial cell adhesion molecule
WO2015048477A1 (en) 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
WO2016013870A1 (ko) 2014-07-22 2016-01-28 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
RU2021124437A (ru) 2015-04-03 2021-09-29 Еурека Терапьютикс, Инк. Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
KR101790669B1 (ko) 2015-10-14 2017-10-26 아주대학교산학협력단 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도
WO2017204606A1 (ko) 2016-05-27 2017-11-30 오름테라퓨틱 주식회사 세포질 침투 항체 및 이의 용도
KR101836392B1 (ko) 2016-08-17 2018-03-08 한림대학교 산학협력단 사이클릭 펩타이드를 포함하는 백신 조성물, 사이클릭 펩타이드에 대한 항체 또는 이를 포함하는 항암 조성물
US20200339681A1 (en) 2017-11-16 2020-10-29 Orum Therapeutics Inc. Antibody inhibiting activated ras in cell by internalizing into cytosol of cell, and use thereof
KR20190143826A (ko) 2018-06-21 2019-12-31 오름테라퓨틱 주식회사 세포/조직 특이적 세포 침투 항체

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134027A2 (en) * 2008-04-30 2009-11-05 Ajou University Industry-Academic Cooperation Foundation Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
KR20100045683A (ko) * 2008-10-24 2010-05-04 아주대학교산학협력단 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도
US20110263829A1 (en) * 2008-11-11 2011-10-27 Ajou University Industry Academic Cooperation Foundation Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same
CN101402675A (zh) * 2008-11-28 2009-04-08 中国人民解放军第三军医大学第三附属医院 一种靶向抑制ανβ3阳性细胞增殖的环肽
CN103874710A (zh) * 2011-04-01 2014-06-18 耶鲁大学 细胞渗透型抗dna抗体和其抑制dna修复的用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DONG-SIK KIM等: "Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 *
TOMOYUKI TANAKA等: "Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affnity and impair oncogenic transformation", 《THE EMBO JOURNAL》 *
TOMOYUKI TANAKA等: "Single Domain Intracellular Antibodies: A Minimal Fragment For Direct In Vivo Selection of Antigen-specific Intrabodies", 《J. MOL. BIOL.》 *
TOMOYUKI TANAKA等: "Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS", 《THE EMBO JOURNAL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111936521A (zh) * 2017-11-16 2020-11-13 奥隆制药 通过内化到细胞胞浆中抑制细胞中活化的Ras的抗体及其用途

Also Published As

Publication number Publication date
BR112017001306A2 (pt) 2018-01-30
IL250137A0 (en) 2017-03-30
KR101732553B1 (ko) 2017-05-08
IL250137B (en) 2020-05-31
JP2017529870A (ja) 2017-10-12
US10851177B2 (en) 2020-12-01
AU2015292956B2 (en) 2020-04-02
AU2015292956A1 (en) 2017-02-09
MX2017001012A (es) 2018-06-19
RU2017103679A (ru) 2018-08-06
EP3173099B1 (en) 2020-03-04
EP3173099A1 (en) 2017-05-31
KR20160033670A (ko) 2016-03-28
CA2955265A1 (en) 2016-01-28
EP3173099A4 (en) 2018-03-14
KR20160011599A (ko) 2016-02-01
JP6798988B2 (ja) 2020-12-09
US20170158777A1 (en) 2017-06-08
KR101602876B1 (ko) 2016-03-11

Similar Documents

Publication Publication Date Title
EP3173428B1 (en) Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
CN106999575A (zh) 使用能够穿透细胞质的完整免疫球蛋白类型的抗体抑制在细胞中活化的ras的方法及其用途
US20220298220A1 (en) Neuropilin-1 Specific Binding Peptide, Fusion Protein Fused with Same, and Use Thereof
KR102163305B1 (ko) 세포의 세포질에 침투하여 세포내 활성화된 Ras를 억제하는 항체 및 이의 용도
US11155641B2 (en) Cytosol-penetrating antibody and use thereof
HK1240492A1 (en) Method for suppressing ras activated in cell by using antibody having cytoplasm penetration capacity and complete immunoglobulin form, and use for same
HK1240599A1 (en) Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
EP3466970A1 (en) Cytosol-penetrating antibody and use thereof
NZ749020B2 (en) Cytosol-penetrating antibody and use thereof
HK40008311A (en) Cytosol-penetrating antibody and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1240492

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170801

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1240492

Country of ref document: HK